Cochrane · systematic review · CD012346
Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease
Pollok, J, van Agteren, JEM, Carson‐Chahhoud, KV · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
2
Included studies
NR
No studies 2 · 14.3%Ungraded 0 · 0%Very low 12 · 85.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tricylic antidepressant compared to placebo for the treatment of depression in chronic obstructive pulmonary disease
Population: COPD with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in depressive symptoms Tricylic antidepressant vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Adverse events (disease‐related: all physical symptoms); Tricylic antidepressant vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Change in quality of life Tricylic antidepressant vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Change in dyspnoea Tricylic antidepressant vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision |
Change in FEV1 (l) Tricylic antidepressant vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Change in exercise tolerance ‐ not reported Tricylic antidepressant vs placebo | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Change in hospital utilisation ‐ not measured Tricylic antidepressant vs placebo | no estimate extracted | NR | No studies |
Selective serotonin reuptake inhibitor compared to placebo for the treatment of depression in chronic obstructive pulmonary disease
Population: chronic obstructive pulmonary disease (COPD) with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean difference in depressive symptoms (from baseline to end of Selective serotonin reuptake inhibitor vs placebo | no estimate extracted | 2 studies · 148 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events (nausea, dizziness) Selective serotonin reuptake inhibitor vs placebo | no estimate extracted | 3 studies · 171 participants | Very low Downgraded: risk of bias, imprecision |
Change in quality of life Selective serotonin reuptake inhibitor vs placebo | no estimate extracted | 2 studies · 148 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Change in dyspnoea Selective serotonin reuptake inhibitor vs placebo | no estimate extracted | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Change in FEV1 (l) Selective serotonin reuptake inhibitor vs placebo | no estimate extracted | 2 studies · 148 participants | Very low Downgraded: risk of bias, imprecision |
Change in exercise tolerance measured using a 6‐minute walk test; Selective serotonin reuptake inhibitor vs placebo | no estimate extracted | 2 studies · 148 participants | Very low Downgraded: risk of bias, imprecision |
Change in hospital utilisation ‐ not measured Selective serotonin reuptake inhibitor vs placebo | no estimate extracted | NR | No studies |